Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Venturini, A."'
Autor:
Lu Wang, Soren Germer, Achim A. Jungbluth, Katerina Politi, Peter Smibert, Lee Spraggon, Elisa Venturini, Pang-Dian Fan, Harold E. Varmus, Emmet Jordan, Gregory J. Riely, Helena Alexandra Yu, Anitha D. Jayaprakash, Mark G. Kris, Giuseppe Narzisi, Christine M. Lovly, Nicolas Robine, Marc Ladanyi
Publikováno v:
Journal of Clinical Oncology. 35:9043-9043
9043 Background: Overcoming AR to EGFR TKIs remains challenging, and in many cases the mechanisms are still unclear. To identify novel mechanisms of resistance to EGFR TKIs, we performed a forward genetic screen using transposon mutagenesis in EGFR-m
Autor:
Maurizio Nicodemo, Marco Venturini, Lucia Cavallini, Gianluigi Lunardi, Maria O. Vannozzi, Andrea Armirotti
Publikováno v:
Journal of Clinical Oncology. 26:5652-5653
Autor:
Salvatore Siena, Evaristo Maiello, Antonio Rinaldi, Samantha Di Donato, Angela Prestifilippo, Federico Grifalchi, Enrico Vasile, C. Barbara, Luisa Toffolatti, Alfredo Butera, Fotios Loupakis, Stefano Cordio, Filippo Venturini, Federico Cappuzzo, Elena Zafarana, Romano Danesi, Alfredo Falcone, Marzia Del Re, Tiziana Latiano, Miriam Ricasoli
Publikováno v:
Journal of Clinical Oncology. 31:11058-11058
11058 Background: DPD deficiency is an inherited syndrome resulting from loss-of-function mutations within the DPYD gene. The IVS14+1G>A variant is associated with DPD deficiency as a result of a 165-bp deletion in the DPD mRNA. A rare mutation, 2846
Autor:
Erica Bonazzina, Andrea Bianchi, Salvatore Siena, Giovanna Marrapese, Lisa Pietrogiovanna, Filippo Venturini, Alessio Amatu, Catia Moutinho, Katia Bencardino, Alessandro Belotti, Alessandra Gambaro, Manel Esteller
Publikováno v:
Journal of Clinical Oncology. 31:3581-3581
3581 Background: O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein removing mutagenic and cytotoxic adducts from O6-guanine in DNA. Approximately 40% of colorectal cancers (CRCs) display MGMT deficiency due to promoter hypermethyl
Autor:
Stefania Gori, Francesco De Lorenzo, Carmine Pinto, Gianmauro Numico, Marco Venturini, Massimo Di Maio, Giovanni Ucci, Maurizio Cancian
Publikováno v:
Publons
e19592 Background: The growing demand and the resources shortage are pushing toward more efficient models of survivorship care delivery. The interface between the MO, the specialists involved in FU and Primary Care Physicians (PCP) should be optimize
Autor:
Alessio Amatu, Salvatore Siena, Roberta Schiavo, Calogero Lauricella, Andrea Sartore-Bianchi, Alessandro Belotti, Giovanna Marrapese, Felicia Giacobbe, Katia Bencardino, Filippo Venturini, Alessandra Gambaro, Catia Moutinho, Andrea Cassingena, Andrea Sporchia, Manel Esteller
Publikováno v:
Journal of Clinical Oncology. 30:3570-3570
3570 Background: O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Roughly 40% of colorectal cancers (CRCs) display MGMT deficiency due to promoter hypermethylat
Autor:
Patrizia Piccioli, Giancarlo Bisagni, M. Venturini, L. Del Mastro, Claudia Bighin, Gruppo Italiano Mammella, Riccardo Ponzone, Ornella Garrone, Gianluigi Lunardi, P. Marroni, P. Driol, M. Porpiglia, S. Giraudi
Publikováno v:
Journal of Clinical Oncology. 29:515-515
515 Background: BMI is associated with an increased risk of BC in postmenopausal women. Moreover, BC overweight women have poorer prognosis compared to women with normal weight. Data from ATAC (the anastrozole, tamoxifen alone or in combination study
Autor:
C. Schumacher, Robert C. F. Leonard, F. Erdkamp, S. Maumus-Robert, J. De Mouzon, G. Carteni, H. Lueck, M. Namer, Brian Richard Bird, M. Gozy, Gerald Batist, Günther G. Steger, P. Ronga, Agustí Barnadas, E. Albuisson, S. Antolín Novoa, Krzysztof Krzemieniecki, M. Venturini, Matti Aapro
Publikováno v:
Journal of Clinical Oncology. 29:e11556-e11556
e11556 Background: Metastatic breast cancer (MBC) is a heterogeneous disease with many treatment options, including single-agent or combination chemotherapy. We analyzed in a real-life setting the therapeutic decision for treating MBC with non-pegyla
Autor:
Monica Giordano, Andrea Michelotti, Ornella Garrone, Claudia Bighin, Luca Boni, M. Venturini, Teresa Gamucci, N. Olmeo, Stefania Gori, L. Del Mastro
Publikováno v:
Journal of Clinical Oncology. 28:528-528
528 Background: To evaluate the role of LHRHa-induced ovarian suppression in preserving the ovarian function (OF) during chemotherapy (CT), a phase III trial was carried out. Methods: Main eligibility criteria: stage I-III premenopausal BC patients (
Autor:
S. De Placido, Armando Santoro, A. De Matteis, M. Venturini, Evaristo Maiello, Salvatore Siena, Francesco Giotta, L. Manzione, Bruno Massidda, Settimio Rossi
Publikováno v:
Journal of Clinical Oncology. 28:e11022-e11022
e11022 Background: The NEMESI study observed the clinical practice adopted in Italian Oncology institutions focusing on ER, ki67, and HER2 status in EBC adjuvant treatment. Methods: NEMESI describe...